Figure S4 from Ccr2⁺ Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma за авторством Dahihm Kim (16546203)

Предмети:

Figure S5 from Ccr2⁺ Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma за авторством Dahihm Kim (16546203)

Предмети:

Table S1 from Ccr2⁺ Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma за авторством Dahihm Kim (16546203)

Предмети:

Figure S1 from Ccr2⁺ Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma за авторством Dahihm Kim (16546203)

Предмети:

Figure S2 from Ccr2⁺ Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma за авторством Dahihm Kim (16546203)

Предмети:

Table S3 from Ccr2⁺ Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma за авторством Dahihm Kim (16546203)

Предмети:

Figure S3 from Ccr2⁺ Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma за авторством Dahihm Kim (16546203)

Предмети:

Supplementary Table S2 from Histone Methyltransferase NSD2 Activates PKCα to Drive Metabolic Reprogramming and Lenalidomide Resistance in Multiple Myeloma за авторством Phyllis S.Y. Chong (17141520)

Предмети:

Supplementary Table S1 from Histone Methyltransferase NSD2 Activates PKCα to Drive Metabolic Reprogramming and Lenalidomide Resistance in Multiple Myeloma за авторством Phyllis S.Y. Chong (17141520)

Предмети:

Table ST7 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma за авторством Ossia M. Eichhoff (14964145)

Предмети:

Table ST2 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma за авторством Ossia M. Eichhoff (14964145)

Предмети:

Table ST3 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma за авторством Ossia M. Eichhoff (14964145)

Предмети:

Table ST8 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma за авторством Ossia M. Eichhoff (14964145)

Предмети:

Table ST4 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma за авторством Ossia M. Eichhoff (14964145)

Предмети:

Table ST6 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma за авторством Ossia M. Eichhoff (14964145)

Предмети:

Table ST1 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma за авторством Ossia M. Eichhoff (14964145)

Предмети:

Table ST9 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma за авторством Ossia M. Eichhoff (14964145)

Предмети:

Table ST5 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma за авторством Ossia M. Eichhoff (14964145)

Предмети:

Supplementary Data from <i>N</i>⁶-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer за авторством Jiachun Su (16990970)

Предмети:

Supplementary Table S1 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition за авторством Yufang Bao (15386826)

Предмети: